EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis - 2021 update
- PMID: 34166721
- DOI: 10.1016/j.jhep.2021.05.025
EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis - 2021 update
Abstract
Non-invasive tests are increasingly being used to improve the diagnosis and prognostication of chronic liver diseases across aetiologies. Herein, we provide the latest update to the EASL Clinical Practice Guidelines on the use of non-invasive tests for the evaluation of liver disease severity and prognosis, focusing on the topics for which relevant evidence has been published in the last 5 years.
Keywords: NASH; cirrhosis; decompensation; elastography; serum markers of fibrosis.
Copyright © 2021 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
Conflict of interest statement
Conflict of interest LC reports grant support from Gilead; consultant/advisory roles with Allergan, Alexion, Echosens, Gilead, Intercept, MSD, Novo Nordisk, Pfizer, and Servier; and sponsored lectures for Abbvie, Echosens, Gilead, Intercept, Novo Nordisk. SP reports consultant/advisory roles with AbbVie, Gilead, Intercept, Novordisk, and Pfizer; and sponsored lectures for Echosens, and Gilead. MT reports grant support from Novo Nordisk Foundation; sponsored lectures for Echosens, Siemens Healthcare, and Danish Agriculture & Food Council; and consulting fees from GE Healthcare. JB reports grants from Echosens, Intercept, and Inventiva; consulting fees from Echosens, Siemens, Diafir and Intercept; sponsored lectures for Echosens, Gilead, Intercept, Lilly and Siemens; consultant/advisory roles with BMS, Gilead, Intercept and Pfizer; and travel support from Gilead and Novartis. ET reports grant support from EU Horizon 2020 Grant for LiverScreen. AB, MF-R, and NC, report no conflict of interest. Please refer to the accompanying ICMJE disclosure forms for further details.
Comment in
-
Poor performance of FIB-4 in elderly individuals at risk for chronic liver disease - implications for the clinical utility of the EASL NIT guideline.J Hepatol. 2022 Jan;76(1):245-246. doi: 10.1016/j.jhep.2021.08.017. Epub 2021 Aug 28. J Hepatol. 2022. PMID: 34461208 No abstract available.
-
Reply to: Correspondence on "EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis - 2021 update".J Hepatol. 2022 Jan;76(1):251-252. doi: 10.1016/j.jhep.2021.10.008. Epub 2021 Nov 4. J Hepatol. 2022. PMID: 34742599 No abstract available.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
